Accessibility Menu
 
Amplia Therapeutics logo

Amplia Therapeutics

(OTC) INNMF

Current Price$0.08
Market Cap$41.05M
Since IPO (2016)-49%
5 Year-64%
1 Year+67%
1 Month-10%

Amplia Therapeutics Financials at a Glance

Market Cap

$41.05M

Revenue (TTM)

$5.79M

Net Income (TTM)

$13.95M

EPS (TTM)

$-0.01

P/E Ratio

-6.20

Dividend

$0.00

Beta (Volatility)

0.29 (Low)

Price

$0.08

Volume

50

Open

$0.08

Previous Close

$0.08

Daily Range

$0.08 - $0.08

52-Week Range

$0.03 - $0.27

INNMF News

No articles available.

INNMF: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Amplia Therapeutics

Industry

Biotechnology

CEO

Christopher J. Burns, PhD

Headquarters

Melbourne, VIC 3000, AU

INNMF Financials

Key Financial Metrics (TTM)

Gross Margin

93%

Operating Margin

-5%

Net Income Margin

-3%

Return on Equity

-27%

Return on Capital

-25%

Return on Assets

-18%

Earnings Yield

-16.13%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$41.05M

Shares Outstanding

513.07M

Volume

50

Short Interest

0.00%

Avg. Volume

7.52K

Financials (TTM)

Gross Profit

$3.57M

Operating Income

$6.52M

EBITDA

$6.78M

Operating Cash Flow

$6.89M

Capital Expenditure

$2.07K

Free Cash Flow

$6.89M

Cash & ST Invst.

$10.86M

Total Debt

$13.89K

Amplia Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$36.30K

-101.5%

Gross Margin

0.00%

N/A

Market Cap

$41.05M

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

$4.00M

-254.2%

EBITDA

$6.96M

-99.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$28.48M

+733.5%

Accounts Receivable

$6.40M

+78.0%

Inventory

$0.00

N/A

Long Term Debt

$595.19K

+982.4%

Short Term Debt

$83.84K

-96.2%

Return on Assets

-17.81%

N/A

Return on Invested Capital

-24.88%

N/A

Free Cash Flow

$8.00M

-125.8%

Operating Cash Flow

$8.00M

-125.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZIVOZIVO Bioscience, Inc.
$9.30+7.14%
CVALFCovalon Technologies Ltd.
$1.25+0.81%
CYYNFCynata Therapeutics Limited
$0.22+0.00%
ACHFFArch Biopartners Inc.
$0.40-9.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
CMCSAComcast
$29.02+0.00%
NVDANvidia
$172.70-0.03%
INTCIntel
$43.87-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%

Questions About INNMF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.